Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2016 | 09-2016 | 06-2016 | 03-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -24,427 | -19,427 | -13,550 | -8,506 | -24,502 |
| Depreciation Amortization | 684 | 513 | 343 | 171 | 684 |
| Accounts payable and accrued liabilities | 33 | -401 | -1,114 | -489 | 1,447 |
| Other Working Capital | -1,756 | -1,849 | -2,453 | -2,457 | 4,030 |
| Other Operating Activity | 3,530 | 3,239 | 3,853 | 3,228 | 931 |
| Operating Cash Flow | $-21,937 | $-17,924 | $-12,923 | $-8,053 | $-17,410 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | N/A | -6 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $-6 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 3,635 | 3,635 | 3,635 | 3,635 | 14,204 |
| Other Financing Activity | 5,289 | 5,289 | 0 | 0 | 0 |
| Financing Cash Flow | $8,924 | $8,924 | $3,635 | $3,635 | $14,204 |
| Beginning Cash Position | 14,179 | 14,179 | 14,179 | 14,179 | 17,392 |
| End Cash Position | 1,166 | 5,178 | 4,891 | 9,761 | 14,179 |
| Net Cash Flow | $-13,013 | $-9,001 | $-9,288 | $-4,418 | $-3,213 |
| Free Cash Flow | |||||
| Operating Cash Flow | -21,937 | -17,924 | -12,923 | -8,053 | -17,410 |
| Capital Expenditure | N/A | N/A | N/A | N/A | -6 |
| Free Cash Flow | -21,937 | -17,924 | -12,923 | -8,053 | -17,416 |